Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
56.97 USD -0.26% Intraday chart for Incyte Corporation -1.30% -9.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Trial of Insider Trading Case Against Former Medivation Employee Begins in California MT
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says MT
Transcript : Incyte Corporation - Shareholder/Analyst Call
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS) CI
Transcript : Incyte Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:50 AM
Wall Street: a flurry of records, including that of the Nasdaq 'broad CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'. CF
Knight Therapeutics Announces Launch of Minjuvi in Brazil MT
Jefferies Initiates Incyte With Buy Rating, Price Target is $81 MT
BMO Capital Adjusts Price Target on Incyte to $64 From $58, Keeps Market Perform Rating MT
Citigroup Adjusts Price Target on Incyte to $81 From $82, Keeps Buy Rating MT
JMP Securities Downgrades Incyte to Market Perform From Market Outperform MT
Truist Securities Adjusts Price Target on Incyte to $84 From $91, Maintains Buy Rating MT
Stifel Adjusts Price Target on Incyte to $68 From $67, Maintains Hold Rating MT
The market faces a choice Our Logo
RBC Lifts PT on Incyte to $65 From $63 on Model Updates Reflecting Monjuvi Integration, Slightly Improved Jakafi/Opzelura Sales Expectations; Sector Perform Kept MT
ANALYST RECOMMENDATIONS : Biogen, Gsk, Hp Inc, Palantir, Walt Disney... Our Logo
Incyte misses quarterly profit estimates due to higher costs RE
Incyte's Q4 Adjusted Earnings, Revenue Advance MT
Transcript : Incyte Corporation, Q4 2023 Earnings Call, Feb 13, 2024
Earnings Flash (INCY) INCYTE Reports Q4 Revenue $1.01B, vs. Street Est of $1.00B MT
Earnings Flash (INCY) INCYTE Posts Q4 EPS $1.06, vs. Street Est of $1.15 MT
Incyte Corporation Provides Earnings Guidance for 2024 CI
Incyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Incyte Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Chart Incyte Corporation
More charts
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.12 USD
Average target price
76.01 USD
Spread / Average Target
+33.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Incyte Corporation - Nasdaq
  4. News Incyte Corporation
  5. Incyte : Review Period for Incyte's Ruxolitinib New Drug Application Extended by FDA